Pantoprazole
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Pantoprazole: Duodenal obstruction
One-Sentence Summary
Pantoprazole is a proton pump inhibitor originally used for acid-related conditions such as peptic ulcer disease, gastroesophageal reflux disease, esophagitis and Zollinger-Ellison syndrome. Evidence for this prediction includes 1 completed Phase 3 trial directly linked to the indication, 18 publications, and additional Phase 3 and 4 trials in related ulcer settings.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Duodenal obstruction |
| TxGNN Prediction Score | 0.9921 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Pantoprazole irreversibly inhibits the gastric H+/K+ ATPase (the proton pump) in parietal cells. This suppresses acid secretion and allows ulcers to heal. Detailed mechanism-of-action data was not available in the data compiled for this report. This description therefore draws on general pharmacology and the cited reviews.
Peptic ulcers are acid-mediated, and peptic ulcer disease is already among pantoprazole’s original indications. Because the use is already established, this evaluation is mostly a confirmation of existing evidence. It does not identify a new therapeutic opportunity.
Other predicted indications are less well supported:
- Gastrojejunal ulcer: mechanistically plausible, but no trials are registered and the literature is general PPI material (evidence level L4).
- Peptic ulcer perforation: limited to a small clinical study of pantoprazole plus perforation repair and non-operative management series (L3).
- Duodenogastric reflux: only partial mechanistic fit, because pantoprazole does not directly prevent bile reflux (L3).
- Duodenal obstruction: no clear rationale; this is a mechanical condition and the score likely reflects network proximity to duodenal ulcer (L5, Hold).
- Duodenal ulcer: an established on-label use with strong evidence (L1).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02084420 | Phase 3 | Completed | 323 | Ilaprazole vs pantoprazole triple therapy for 7 days for H. pylori eradication in gastric and/or duodenal ulcer patients (multicentre, randomized, double-blind) |
Further trials in related ulcer settings were found under the duodenal ulcer prediction:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00374101 | Phase 3 | Completed | 450 | High vs standard dose PPI after endoscopic therapy for bleeding peptic ulcers; high dose was not better |
| NCT00843063 | Phase 4 | Completed | 161 | Famotidine vs pantoprazole to prevent recurrent aspirin-induced ulcer or erosion |
| NCT02551744 | Not applicable | Completed | 101 | Pantoprazole vs famotidine to prevent recurrent ulcers in thienopyridine users |
| NCT02467621 | Phase 4 | Completed | 3350 | Stress ulcer prophylaxis with a PPI in the ICU (SUP-ICU) |
| NCT00261300 | Phase 3 | Completed | 100 | Long-term pantoprazole in chronic acid-peptic complaints |
| NCT00001191 | Phase 2 | Completed | Not reported | Oral omeprazole and IV pantoprazole in gastric acid hypersecretion (Zollinger-Ellison syndrome) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38384180 | 2024 | RCT | Gut and Liver | Tegoprazan (a potassium-competitive acid blocker) vs active control for endoscopic resection-induced artificial ulcers |
| 38345252 | 2024 | Systematic review / network meta-analysis | Am J Gastroenterol | P-CAB vs PPI for healing grade C/D esophagitis |
| 19938880 | 2009 | Review | Clin Drug Investig | Pantoprazole irreversibly binds the proton pump, with a long duration of action and few identified drug interactions |
| 21534455 | 2011 | Review | Med Arh | PPIs in GERD management; healing correlates with intragastric pH above 3.5 |
| 10450061 | 1999 | Review | Pharmacology | Different PPIs show similar dose-response relationships at the same milligram dose |
| 16961157 | 2006 | Review | Int J Clin Pharmacol Ther | Impact of CYP2C19 polymorphism on PPI action |
| 10638560 | 2000 | Comparative study | Am J Gastroenterol | Pantoprazole vs ranitidine in duodenal ulcer, multicentre study in Brazil |
| 15244210 | 2003 | Comparative study | Hepatogastroenterology | Lansoprazole vs pantoprazole in active duodenal ulcer and H. pylori eradication |
| 38652367 | 2024 | Preclinical (rat) | Inflammopharmacology | Pantoprazole combined with mesenchymal stem cells in experimental gastric ulcer |
| 26439477 | 2016 | Preclinical (rat) | J Nat Med | Crocin against indomethacin-induced gastric lesions, with pantoprazole as a comparator |
Duodenal ulcer literature also includes several older comparative trials, including 7569755 (pantoprazole vs ranitidine, RCT, 1995) and 8180294 (pooled analysis showing significantly better duodenal ulcer healing with pantoprazole 40 mg than ranitidine 300 mg at 2 and 4 weeks).
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 19608 | Adicid 40mg Injection | Vial of 1 injection | Not stated |
| 175021 | Proton 40mg Tablet | Strip of 10 tablets | Not stated |
| 174002 | Pantocid 80 Dual-Release Tablet | Strip of 15 tablets | Not stated |
| 173922 | Pantocid IV Injection | Vial of 1 injection | Not stated |
| 96957 | Gempan 40mg Tablet | Strip of 10 tablets | Not stated |
All 20 licences are valid single-ingredient products, and none are cancelled. Both injectable and oral tablet forms are marketed.
Safety Considerations
- Drug interactions: 597 interactions were identified. Examples:
- Major: acalabrutinib, atazanavir.
- Moderate: hydrochlorothiazide, atorvastatin, bosutinib, fenofibrate, alpelisib, apalutamide, amphotericin B, amikacin, bumetanide.
- Minor: acetylsalicylic acid, cyanocobalamin, axitinib, bortezomib.
Please refer to the package insert for warnings and other safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Active peptic ulcer disease is an established use of pantoprazole. It is supported by a completed Phase 3 randomized trial, other ulcer-related trials, and comparative studies showing faster healing than ranitidine. Because this is on-label use, the decision is about confirming and documenting existing evidence, not pursuing a new indication.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian licences, as the approved-indication text is currently blank
- Detailed mechanism-of-action data
- Verification of the comparator and population for NCT02084420, since its title is truncated
- A review of the major drug interactions (e.g., atazanavir, acalabrutinib), and of the bone-health and vitamin B12 / pernicious anemia associations for long-term use
- Other predicted indications (gastrojejunal ulcer, peptic ulcer perforation, duodenogastric reflux) are research questions needing dedicated clinical evidence; duodenal obstruction should be held
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.